Adarza had been developing the technology for research use in immuno-oncology or cell therapy applications—though it has also been used to study influenza—with plans to begin a commercial rollout this year, according to President and CEO Bryan Witherbee. However, with the spread of COVID-19 this year, the company pivoted further into respiratory diseases and vaccine development, and aims to provide a more detailed view than other antibody tests on the market…
